Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01616758 · ClinicalTrials.gov registry record · Phase 2
Phase II Study of GTx024 in Women With Metastatic Breast Cancer
A Phase 2 study, sponsored by GTx.
- Terminated
- Registry status
- Phase 2
- Development phase
- 22
- Enrollment target
NCT01616758 is a Phase 2 study that was terminated before completion, run by GTx. The registered enrollment target is 22 participants.
The verdict
NCT01616758, a Phase 2 study, was terminated before completion, sponsored by GTx.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 22 participants
- Enrollment target
Study Summary
The primary efficacy analysis will be the clinical benefit at 6 months as measured by a modified Response Evaluation Criteria in Solid Tumors RECIST classification. Key secondary endpoints of objective response rate, progression free survival, time to progression, duration of response, effects on physical function, and effects on tumor progression in women with Androgen Receptor positive breast cancer will also be assessed.
Interventions
- DRUG GTx-024 9mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2013-04 |
| Est. Completion | 2016-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01616758
The ClinicalTrials.gov registry entry for NCT01616758 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 22 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GTx, which has 15 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which GTx-024 9mg is the first listed.
NCT01616758 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01616758 about?
NCT01616758 is a clinical study titled "Phase II Study of GTx024 in Women With Metastatic Breast Cancer". The primary efficacy analysis will be the clinical benefit at 6 months as measured by a modified Response Evaluation Criteria in Solid Tumors RECIST classification. Key secondary endpoints of objective response rate, progression free survival, time to progression, duration of response, effects on ph...
What is the current status of trial NCT01616758?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 22 participants. The study started on 2013-04. Estimated completion is 2016-03.
What interventions are being tested in trial NCT01616758?
The interventions under investigation include: GTx-024 9mg (DRUG).
Who is sponsoring clinical trial NCT01616758?
This trial is sponsored by GTx, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.